Project Office Update November 7, 2013
description
Transcript of Project Office Update November 7, 2013
Project Office UpdateNovember 7, 2013
Jacques E Rossouw
Renewal proposal approved for further development (i.e., developing Acquisition Plan)
Budget subject to availability of funds--sequester, etc.
Initial approval for 3 year period--period could be adjusted depending
on outcome of BEE/Council WG
Renewal
By 2050 number of US women aged >65 will have doubled to 49 million.
CVD deaths account for 36% of total deaths in older women
By 2016 WHI projects to have 85,000 participants with mean age 83 (range 66-102), N=52K or 58% age >80.
In MRC project 21K women (including 5.8K AA, 2.2K Hispanic) by 2016
Unique Strengths of WHI
Expand knowledge about the determinants of CVD in older women (and conversely determinants of successful aging with absence of CVD) Particular focus on understudied conditions of
heart failure, atrial fibrillation, periperal arterial disease, aortic stenosis
Fully utilize the new data and bloods from the LLS subcohort
Current and Future Mission
Expand the study as a scientific resource for the research community GWAS=32K, ExomeChip=25K, Metabochip=15K
Mentor young investigators ~150 mentored during current renewal 2010 Chicago Workshop to date has led to 21 approved
manuscript proposals and 5 published papers Facilitate a new generation of large simple trials
Cocoa and multivitamin (Manson) Physical Activity (Stefanick/LaCroix) Vitamin D (Jackson)
Continue research into utility of CMS data
Current and Future Mission
Determine whether race/ethnic differences in CVD risk are explained by SES, risk markers, genomics, life habits, medical coverage, or environmental factors
Determine influence of risk factors (including genomic) and exposures on heart failure (including HF with preserved systolic function), AF, AS, PAD
Create CVD survivor cohort by following up incident events through CMS for recurrence, morbidity/mortality, quality of care, healthcare utilization and expenditures
Selected Research Examples
Integrate gene variants, methylation, expression, regulation, metabolome, and biomarkers in systems biology approach to CVD pathways
Determine influence of baseline LTL on successful aging/absence of CVD and the determinants of attrition in LTL and its association with CVD risk
Selected Research Examples
Some Initial Results: Dissemination and Mentoring2010-2015
Total ancillary studies = 225 (April, 2013)• Before 2010 52% led by new investigators• After 2010 63% led by new investigators
Publications = 814 (April, 2013)
• Before 2010 30% led by new investigators• Since 2010 51% led by new investigators
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 20130
5
10
15
20
25
30
35
36
42 2
4 5
9
3 4 58
24
2
9
15
21
15
8
5
4 7 6 2
8
3
83
3
3
3
4
5
8
16
6
Number of Ancillary Studies by Year of Award and WHI Affiliation of PI
New Investigators to WHI WHI Investigators
Year
Num
ber o
f Stu
dies
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 20130
10
20
30
40
50
60
70
80
90
100
110
120
130
1 3 4 2 3 7 7 5
14
40
26 31
4532
53 40
44
65
54
16
1 1 3 39 10 9 8
1424 25 29
41
57
73
19
WHI Publications by Year and WHI Affilia-tion of Lead Author
New Investigators to WHI WHI Investigators
Year
Num
ber o
f Pub
licat
ions
WHI cohort study Increasingly productive Cost-effective High impact (~2400 cites per year since 2010)
Mentoring and dissemination efforts are showing results
Need more focus on CVD in older women
Conclusions